MetaCap

Inhibikase Therapeutics Inc. Company Profile

NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.32+0.02 (+1.54%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Inhibikase Therapeutics at a glance

Inhibikase Therapeutics Inc. (NASDAQ: IKT) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Wilmington, DE. Inhibikase Therapeutics is led by Mr. Mark T. Iwicki and employs about 35 people. The company's shares have traded publicly since 2020.

At a market capitalization of $182.4 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001750149, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Inhibikase Therapeutics do?

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Business description based on the company's public filings.

Company information

Legal name
Inhibikase Therapeutics Inc.
Ticker
NASDAQ: IKT
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Mark T. Iwicki
Employees
35
Headquarters
1000 N. West Street, Wilmington, DE, United States
Phone
302 295 3800
IPO year
2020
Market cap
$182.35M
SEC CIK
0001750149
Latest annual report
10-K · Mar 26, 2026

Companies similar to Inhibikase Therapeutics

IKT peer companies
CompanyPrice% ChgMarket capCompare
ARTVArtiva Biotherapeutics Inc.3.78-1.31%$186.85Mvs IKT
CGENCompugen Ltd.1.84-2.13%$174.29Mvs IKT
LCTXLineage Cell Therapeutics Inc.0.7719-5.87%$195.26Mvs IKT
CABACabaletta Bio Inc.0.9361-7.32%$201.94Mvs IKT
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs IKT
PALIPalisade Bio Inc.0.8399-9.24%$150.74Mvs IKT
ALLOAllogene Therapeutics Inc.0.6277-5.88%$217.48Mvs IKT
STROSutro Biopharma Inc.8.60-1.38%$142.77Mvs IKT

Related